Clevidipine
- Generic Name
- Clevidipine
- Brand Names
- Cleviprex
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23Cl2NO6
- CAS Number
- 167221-71-8
- Unique Ingredient Identifier
- 19O2GP3B7Q
- Background
Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
- Indication
For the reduction of blood pressure when when oral antihypertensive therapy is not feasible or not desirable.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General Anesthesia
- Conditions
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 64
- Registration Number
- NCT06063772
Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke
- Conditions
- Interventions
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- ProMedica Health System
- Target Recruit Count
- 80
- Registration Number
- NCT05175547
- Locations
- 🇺🇸
ProMeedica Toledo Hospital, Toledo, Ohio, United States
Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 40
- Registration Number
- NCT03719001
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)
- Conditions
- Interventions
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- University of Zurich
- Registration Number
- NCT03300479
- Locations
- 🇨🇭
University Hospital Zurich, Zurich, Switzerland
Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)
- Conditions
- Interventions
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Henry Ford Health System
- Registration Number
- NCT02011321
- Locations
- 🇺🇸
Henry Ford hospital, Detroit, Michigan, United States
Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)
- Conditions
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 22
- Registration Number
- NCT01938547
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Stanford Medical Center, Stanford, California, United States
The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2013-07-29
- Lead Sponsor
- Mario Ammirati
- Registration Number
- NCT01910532
- Locations
- 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01645111
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
The Effect of Clevidipine on Intracranial Pressure and Cerebral Perfusion Pressure (CCP) in Brain Injured Patients
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Columbia University
- Registration Number
- NCT01526876
Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection
- Conditions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Duke University
- Registration Number
- NCT01480531
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.